Biomerica found using ticker (BMRA) have now 4 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 13 and 9.5 calculating the mean target price we have 10.88. With the stocks previous close at 5.14 this indicates there is a potential upside of 111.7%. The day 50 moving average is 5.81 while the 200 day moving average is 7.08. The company has a market capitalisation of $77m. Company Website: http://www.biomerica.com
Biomerica, a biomedical technology company, together with its subsidiaries, develops, patents, manufactures, and markets diagnostic and therapeutic products or detection and/or treatment of medical conditions and diseases worldwide. The company’s diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient’s body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians’ offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome (IBS) therapy technology and diagnostic-guided therapy that is designed to allow physicians to identify specific foods that when removed from the patient’s diet can alleviate the patient’s IBS symptoms; Helicobacter pylori products; and develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica was founded in 1971 and is headquartered in Irvine, California.